By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Our 3-day Digital Redefining Early-Stage Investments (RESI) January Conference came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovator’s Pitch Challenge (IPC). Each participating finalist company had a dedicated page featuring a short pitch, executive summary, and other supplementary materials available for viewing.
The Digital RESI January Live Agenda is open to registered attendees until February 13, so there’s still time to check out the Digital RESI January Live Agenda for virtual exhibit of innovative technologies across all life science & healthcare sectors!
The RESI Team would like to thank every IPC company for their virtual presentations, and the hard work to promote their technologies to our RESI community. The Top 3 winners will be awarded with free tickets to future RESI conferences. Congratulations to the Top 3 winners, and thanks to all for voting!
First Place: Concarlo Holdings
Concarlo Holdings, LLC is a precision medicine company focusing on unmet needs in oncology: developing therapeutics and diagnostics to extend the lives of cancer patients, beginning with women with metastatic breast cancer.
Check Concarlo Holdings’ Dedicated Page
Tied for Second Place: BCell Solutions
BCell Solutions, Inc., is a pre-clinical biopharmaceutical company commercializing a family of highly anti-inflammatory, small molecule peptides. Uses include treatment of chronic inflammation, acute/hyper-inflammation, and neuroinflammation. Our lead indication is kidney disease, supported by data from two animal models showing BCS Immunotherapy’s successful reversal of loss of kidney autoregulatory function, a key element of chronic kidney disease and renal failure.
Check BCell Solutions’ Dedicated Page
Tied for Second Place: Surgical Innovation Associates
Surgical Innovation Associates (SIA) is a Chicago-based medical device spin-out from Northwestern University with FDA 510(k) clearance, CE Mark, and rapidly growing sales for its first product, DuraSorb™ – a patented absorbable surgical mesh in the $1B+ general and reconstructive surgery market. In only a few months on the market, we have grown sales to >$100k/month at >80% gross profit margin. SIA is led by an industry-experienced management team and supported by a veteran Board of Directors as well as a reputable medical advisory board. Existing investors include ex-CEO’s and CFO’s of publicly traded medical device corporations (Baxter Healthcare, Baxalta, etc.), KOL surgeons from leading universities (Northwestern, NYU, Northshore) and respected angel groups from across the country (Harvard Business School Angels, Gopher Angels, Ann Arbor Angels). We’ve also received $2M of NCI SBIR grants with an opportunity for $4M of follow-on grant funding, providing investors with great leverage. We are now seeking a $10M Series B predominantly to fuel sales growth, with a target closing in Q1 2021.
Next Phase Newsletter 
Leave a comment